Literature DB >> 17428446

An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone.

Xiyong Liu1, Bingsen Zhou, Shu Mi, Lijun Xue, Jennifer Shih, Janice Lee, Jennifer Chau, Frank Un, Yun Yen.   

Abstract

Mechanistic aberrations leading to Gemcitabine (2',2'-dFdCyd,2,2-difluorodeoxycytidine, Gem) resistance may include alteration in its transport, metabolism and incorporation into DNA. To explore the mechanism of Gem resistance, the restriction fragment differential display PCR (RFDD-PCR) was employed to compare the mRNA expression patterns of KBGem (Gem resistant), KBHURs (hydroxyurea resistant) and KBwt (parental KB cell). Nine gene fragments were overexpressed specifically in the KBGem clone. Sequencing and BLAST results showed that three fragments represent cytochrome C oxidase (CCOX, respiration complex IV) subunit III (CCOX3). The cDNA microarray confirmed that the mRNAs of CCOX and ATP synthase subunits were upregulated in KBGem as compared to KBwt and KBHURs. The increase in CCOX1 protein and activity led to the increase of free ATP concentration, which is consistent with the gene expression profile of KBGem. Furthermore, the sensitivity to Gem could be reversed by sodium azide, a CCOX inhibitor. Following the treatment of sodium azide, the cellular accumulation of [3H]-Gem increased in a dose (of azide)-dependent manner, which is associated with increase of [3H]-Gem incorporation into DNA in KBGem. In summary, an increase of CCOX activity and free ATP level may reduce the transport, metabolism and DNA incorporation of Gem, resulting in Gem resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428446      PMCID: PMC1950577          DOI: 10.1016/j.bcp.2007.03.014

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  44 in total

Review 1.  Cytochrome c oxidase--structure, function, and physiology of a redox-driven molecular machine.

Authors:  O-M H Richter; B Ludwig
Journal:  Rev Physiol Biochem Pharmacol       Date:  2003-02-21       Impact factor: 5.545

Review 2.  A comprehensive model for the allosteric regulation of Class Ia ribonucleotide reductases.

Authors:  Barry S Cooperman; Ossama B Kashlan
Journal:  Adv Enzyme Regul       Date:  2003

3.  Chronic treatment with azide in situ leads to an irreversible loss of cytochrome c oxidase activity via holoenzyme dissociation.

Authors:  Scot C Leary; Bruce C Hill; Carrie N Lyons; Christopher G Carlson; Denise Michaud; Claudia S Kraft; Kenton Ko; D Moira Glerum; Christopher D Moyes
Journal:  J Biol Chem       Date:  2002-01-16       Impact factor: 5.157

4.  Characterization of a novel metabolic strategy used by drug-resistant tumor cells.

Authors:  Mary-Ellen Harper; Andreas Antoniou; Elizabeth Villalobos-Menuey; Alicia Russo; Richard Trauger; Minda Vendemelio; Amanda George; Richard Bartholomew; Dennis Carlo; Azhar Shaikh; Jami Kupperman; Evan W Newell; Ivan A Bespalov; Susan S Wallace; Ye Liu; Jeffrey R Rogers; Gregory L Gibbs; Jack L Leahy; Robert E Camley; Robert Melamede; M Karen Newell
Journal:  FASEB J       Date:  2002-10       Impact factor: 5.191

5.  Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance.

Authors:  B Zhou; X Mo; X Liu; W Qiu; Y Yen
Journal:  Cytogenet Cell Genet       Date:  2001

6.  Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells.

Authors:  Bingsen Zhou; Shu Mi; Xueli Mo; Jennifer Shih; Jeffery Tsai; Edward Hu; Margaret Hsu; Kristie Kay; Yun Yen
Journal:  Anticancer Res       Date:  2002 May-Jun       Impact factor: 2.480

Review 7.  Nucleoside analogues and nucleobases in cancer treatment.

Authors:  Carlos M Galmarini; John R Mackey; Charles Dumontet
Journal:  Lancet Oncol       Date:  2002-07       Impact factor: 41.316

Review 8.  Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignancies.

Authors:  Carlos M Galmarini; Lars Jordheim; Charles Dumontet
Journal:  Leuk Lymphoma       Date:  2003-07

9.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.

Authors:  José García-Manteiga; Míriam Molina-Arcas; F Javier Casado; Adela Mazo; Marçal Pastor-Anglada
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

10.  Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.

Authors:  Emma Månsson; Emma Flordal; Jan Liliemark; Tatiana Spasokoukotskaja; Howard Elford; Svetlana Lagercrantz; Staffan Eriksson; Freidoun Albertioni
Journal:  Biochem Pharmacol       Date:  2003-01-15       Impact factor: 5.858

View more
  1 in total

Review 1.  microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.

Authors:  Martino Marco Gabra; Leonardo Salmena
Journal:  Front Oncol       Date:  2017-10-30       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.